Integra LifeSciences (NASDAQ:IART) Stock Price Down 7.7% Following Analyst Downgrade

Integra LifeSciences Holdings Corporation (NASDAQ:IART)’s stock price fell 7.7% on Monday after Wells Fargo & Company lowered their price target on the stock from $13.00 to $12.00. Wells Fargo & Company currently has an equal weight rating on the stock. Integra LifeSciences traded as low as $10.53 and last traded at $10.50. 281,983 shares were traded during mid-day trading, a decline of 61% from the average session volume of 721,196 shares. The stock had previously closed at $11.38.

A number of other equities analysts also recently issued reports on IART. Citigroup dropped their price target on Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating on the stock in a research note on Friday, October 31st. Truist Financial reiterated a “hold” rating and issued a $13.00 price target (down from $15.00) on shares of Integra LifeSciences in a research report on Monday, November 3rd. JPMorgan Chase & Co. boosted their price objective on shares of Integra LifeSciences from $12.00 to $13.00 and gave the company an “underweight” rating in a research report on Friday, October 31st. Weiss Ratings reissued a “sell (e+)” rating on shares of Integra LifeSciences in a report on Monday, December 29th. Finally, Wall Street Zen raised Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, Integra LifeSciences presently has a consensus rating of “Reduce” and a consensus price target of $14.80.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of IART. Global Retirement Partners LLC acquired a new position in shares of Integra LifeSciences during the 4th quarter worth $25,000. GAMMA Investing LLC boosted its stake in shares of Integra LifeSciences by 55.3% during the 3rd quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company’s stock worth $37,000 after acquiring an additional 913 shares in the last quarter. Osaic Holdings Inc. boosted its stake in shares of Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after acquiring an additional 1,104 shares in the last quarter. AlphaQuest LLC purchased a new position in Integra LifeSciences in the 2nd quarter valued at approximately $73,000. Finally, EMC Capital Management purchased a new position in Integra LifeSciences in the 2nd quarter valued at approximately $75,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

The firm has a fifty day moving average of $11.96 and a 200-day moving average of $13.18. The company has a quick ratio of 1.46, a current ratio of 2.54 and a debt-to-equity ratio of 1.66. The stock has a market capitalization of $815.51 million, a price-to-earnings ratio of -1.55 and a beta of 1.02.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Thursday, February 26th. The life sciences company reported $0.83 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.04. Integra LifeSciences had a positive return on equity of 14.76% and a negative net margin of 31.58%.The business had revenue of $434.93 million during the quarter, compared to analysts’ expectations of $429.62 million. During the same quarter last year, the business posted $0.97 earnings per share. The business’s revenue for the quarter was down 1.7% on a year-over-year basis. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. As a group, sell-side analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.